Genkyotex Reverse Stock Split Takes Effect

    NEXT STORY
    Chi-Med Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in China
    PREV STORY
    CrownBio and Hubrecht Organoid Technology Announce a Strategic Partnership, including Exclusive License to Provide Oncology Organoid-Based Preclinical Drug Development and Validation Services
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Apricus Biosciences Announces the Launch of Vitaros® for the Treatment of Erectile Dysfunction in Lebanon by Elis Pharmaceuticals

    SAN DIEGO, Dec. 27, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical ...

    author_avatar
    NASDAQ Market News

    Interpace Diagnostics Announces Coverage of Its Thyroid Assays by Blue Shield of California

    PARSIPPANY, N.J., April 02, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” ...

    author_avatar
    NASDAQ Market News

    Athenex CEO Informs Shareholders of Unrelated Matter Regarding Past Board Membership at Porton Pharma

    author_avatar
    NASDAQ Market News